Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration

BACKGROUND: Current clinical guidelines recommend epidermal growth factor receptor (EGFR) mutational testing in patients with metastatic non-small cell lung cancer (NSCLC) to predict the benefit of the tyrosine kinase inhibitor erlotinib as first-line treatment. Proteomic (VeriStrat) testing is reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Efimova, Olga, Berse, Brygida, Denhalter, Daniel W., DuVall, Scott L., Filipski, Kelly K., Icardi, Michael, Kelley, Michael J., Lynch, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450357/
https://www.ncbi.nlm.nih.gov/pubmed/28558785
http://dx.doi.org/10.1186/s12911-017-0475-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450357/
https://www.ncbi.nlm.nih.gov/pubmed/28558785
http://dx.doi.org/10.1186/s12911-017-0475-8

Ejemplares similares